Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer
Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer
复制标题
DOI：
10.2217/fon.09.133
复制
发表时间：
2010-01-01
期刊：
影响因子：
3.3
通讯作者：
Metzger, Ralf
中科院分区：
文献类型：
--
作者：
Bollschweiler, Elfriede;Hoelscher, Arnulf H.;Metzger, Ralf
文献综述表明，临床评价不能用于确定“完全缓解”。本文总结了食管癌新辅助放化疗后组织病理学反应分级的不同分类系统。对分析食管鳞状细胞癌（SCC）或腺癌（AC）术前放化疗的研究进行的系统性综述表明，AC和SCC研究之间的病理完全缓解（pCR）率无显著差异。仅分析所施加的辐射剂量表明，AC患者需要比SCC患者更高的剂量才能达到完全缓解。重复化疗不会显著改变所需放射剂量的差异。然而，当肿瘤确实有反应时，AC患者的pCR率随着放化疗剂量的增加而比SCC患者增加得更快。
A review of the literature demonstrated that clinical evaluation cannot be used to determine 'complete response'. The different classification systems of the histopathologic response grading after neoadjuvant radiochemotherapy of esophageal carcinoma are summarized in this report. A systematic review of studies analyzing preoperative chemoradiation of squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus demonstrated no significant difference in pathologic complete response (pCR) rates between the AC and SCC studies. Analyzing only the applied dose of radiation demonstrated that patients with AC required a higher dose than patients with SCC to achieve complete response. Incorporating chemotherapy administration does not markedly change the difference in required radiation dose. However, when the tumor does respond, the rate of pCR with increasing dosage of chemoradiotherapy increases more rapidly in AC patients than in SCC patients.